[CAS NO. 163706-36-3] Cangrelortetrasodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [163706-36-3]

Catalog

HY-19638A

Brand

MCE

CAS

163706-36-3

DESCRIPTION [163706-36-3]

Overview

MDL	MFCD14635359
Molecular Weight	864.29
Molecular Formula	C17H21Cl2F3N5Na4O12P3S2
SMILES	O[C@H]1[C@@H](O)[C@H](N2C3=NC(SCCC(F)(F)F)=NC(NCCSC)=C3N=C2)O[C@@H]1COP(OP(C(Cl)(P(O[Na])(O[Na])=O)Cl)(O[Na])=O)(O[Na])=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Mol Nutr Food Res. 2022 May 1;e2200166.

Summary

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist ^[1] ^[2] .

IC50 & Target

P2Y12 Receptor

In Vitro

Cangrelor tetrasodium is the only potent intravenous direct and specific adenosine diphosphate (ADP) P2Y12 receptor antagonist ^[1] .
Cangrelor tetrasodium has pK _b of 8.6-9.2 for hP2Y12 receptor ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02978040	University Hospital Inselspital, Berne	Coronary Artery Disease\|STEMI - ST Elevation Myocardial Infarction	July 4, 2017	Phase 4
NCT01979445	The Medicines Company	Coronary Artery Disease (CAD)	December 2, 2013	Phase 2
NCT04138641	Isala	STEMI - ST Elevation Myocardial Infarction\|NSTEMI - Non-ST Segment Elevation MI\|Coronary Artery Disease	December 17, 2019
NCT03182855	University of Aarhus	Acute Coronary Syndrome\|Myocardial Infarction\|STEMI - ST Elevation Myocardial Infarction	September 1, 2018	Phase 4
NCT05505591	Universita degli Studi di Genova\|Università degli Studi della Campania Luigi Vanvitelli	Bleeding\|Coronary Artery Disease\|Myocardial Infarction	June 6, 2022
NCT04790032	Federico II University	Percutaneous Coronary Intervention	March 16, 2021
NCT04667078	Fondation Ophtalmologique Adolphe de Rothschild\|Ministry of Health, France	Acute Ischemia	March 2, 2022	Phase 3
NCT01766466	The Medicines Company	Coronary Artery Disease	January 2013	Phase 2
NCT04668144	University of Florida\|Scott R. MacKenzie Foundation	Coronary Artery Disease\|Acute Coronary Syndrome	February 9, 2021	Phase 4
NCT03247738	University of Florida\|Chiesi Farmaceutici S.p.A.	ST Segment Elevation Myocardial Infarction\|Percutaneous Coronary Intervention	November 20, 2017	Phase 4
NCT00699504	The Medicines Company	Healthy	June 2008	Phase 1
NCT03862651	Ospedale Santa Croce-Carle Cuneo	Platelet Aggregation Inhibitors	June 1, 2019	Phase 2
NCT03273075	Medical University of Vienna	Cardiopulmonary Arrest With Successful Resuscitation\|ACS - Acute Coronary Syndrome\|Hypothermia, Induced	September 2017	Phase 4
NCT04927949	University Hospital, Caen\|Terumo Medical Corporation	ST-elevation Myocardial Infarction	June 8, 2021	Phase 4
NCT03043274	Khaled Ziada, MD\|University of Kentucky	STEMI - ST Elevation Myocardial Infarction	January 2017	Phase 4
NCT02733341	The Royal Wolverhampton Hospitals NHS Trust	Acute Coronary Syndrome (ACS)\|High On-treatment Platelet Reactivity (HTPR)\|Microvascular Obstruction (MVO)\|ST-segment Elevation Myocardial Infarction (STEMI)\|Thrombolysis in Myocardial Infarction (TIMI)\|Unstable Angina (UA)	July 21, 2016	Phase 4
NCT04005729	University Medical Centre Ljubljana\|Chiesi Slovenija, d.o.o.	Out-Of-Hospital Cardiac Arrest\|Acute Coronary Syndrome	July 1, 2019	Phase 4
NCT00102674	The Medicines Company	Healthy	March 2005	Phase 1
NCT01156571	The Medicines Company	Atherosclerosis\|Percutaneous Coronary Intervention\|Acute Coronary Syndrome	September 2010	Phase 3
NCT00305162	The Medicines Company	Myocardial Infarction (MI)\|Acute Coronary Syndromes (ACS)	April 2006	Phase 3
NCT04634162	University of Florida\|Scott R. MacKenzie Foundation	Coronary Artery Disease	February 9, 2021	Phase 4
NCT03551964	Faculty Hospital Kralovske Vinohrady\|Charles University, Czech Republic	Acute Myocardial Infarction\|Cardiogenic Shock	August 1, 2018	Phase 4
NCT02765633	Chiesi Farmaceutici S.p.A.	Partial Obstruction of Systemic to Pulmonary Artery Shunt\|Complete Obstruction of Systemic to Pulmonary Artery Shunt	January 3, 2017	Phase 1
NCT03102723	National Heart Centre Singapore\|Tan Tock Seng Hospital\|National University Hospital, Singapore\|Khoo Teck Puat Hospital\|Changi General Hospital\|Sengkang General Hospital	STEMI	October 1, 2017	Phase 2
NCT00385138	The Medicines Company	Atherosclerosis\|Acute Coronary Syndrome (ACS)	September 2006	Phase 3
NCT02943369	Attikon Hospital\|AHEPA University Hospital\|University Hospital, Alexandroupolis	STEMI	July 28, 2017	Phase 4
NCT01852019	The Medicines Company	Coronary Artery Disease	June 2013	Phase 2
NCT00767507	The Medicines Company	Acute Coronary Syndrome (ACS)	October 2008	Phase 2
NCT03048019	Inova Health Care Services	Non-ST Elevation Myocardial Infarction (NSTEMI)	August 23, 2017

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H ₂ O : 125 mg/mL ( 144.63 mM ; Need ultrasonic)

DMSO : 12.5 mg/mL ( 14.46 mM ; ultrasonic and warming and heat to 80°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1570 mL	5.7851 mL	11.5702 mL
5 mM	0.2314 mL	1.1570 mL	2.3140 mL
10 mM	0.1157 mL	0.5785 mL	1.1570 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (115.70 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 1.25 mg/mL (1.45 mM); Clear solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 1.25 mg/mL (1.45 mM); Clear solution; Need ultrasonic
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: 1.25 mg/mL (1.45 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

5′-Adenylic acid, N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-, anhydride with P,P′-(dichloromethylene)bis[phosphonic acid], sodium salt (1:1:4)

5′-Adenylic acid, N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-, monoanhydride with (dichloromethylene)bis[phosphonic acid], tetrasodium salt

AR-C 69931MX

Cangrelor tetrasodium